Arcturus Therapeutics (ARCT) Reports Q2 Loss, Beats Revenue Estimates
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of +21.50% and +18.03%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?